Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination

Recruiting

Phase 3

VAX-31Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination

Sponsor:

Vaxcyte, Inc.

Code:

NCT07425392

Conditions

Pneumococcal Vaccines

Eligibility Criteria

Sex: All

Age: 50+

Healthy Volunteers: Accepted

Interventions

31-valent pneumococcal conjugate vaccine

PCV20

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-03-16. This information was provided to ClinicalTrials.gov by Vaxcyte, Inc. on 2026-03-13.